Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 20Unknown 12Recruiting 11Not yet recruiting 6Terminated 5Active not recruiting 5Withdrawn 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Gastrointestinal 1

Conditions

Hematologic Neoplasms 1Barrett Esophagus 1

Interventions

Cyclophosphamide 128Cisplatin 119Radiotherapy 111pembrolizumab 110Paclitaxel 96Gemcitabine 96Carboplatin 96Nivolumab 76Magnetic Resonance Spectroscopy 76Bevacizumab 76Fluorouracil 74Dexamethasone 73Radiosurgery 66Docetaxel 59Rituximab 58Leucovorin 57Oxaliplatin 55Capecitabine 55Doxorubicin 52fludarabine 51Biopsy 48durvalumab 44Cytarabine 44Drug Therapy 43Etoposide 42fludarabine phosphate 40Pemetrexed 40Radiation 39atezolizumab 36Lenalidomide 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Interventional × Endoscopy × Clear all
NCT05660421 2026-04-27

Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors

Vanderbilt-Ingram Cancer Center

Phase 2 Withdrawn
Other hematologic neoplasm

Hematologic Neoplasms

NCT01209013 2012-05-08

Oedisse

Pinnacle Biologics Inc.

Phase 3 Withdrawn
Gastrointestinal

Barrett Esophagus

Data powered by HemOnc (CC BY 4.0) Colophon âš¡